The Future of Myeloma Care: Emerging Therapies and Novel Approaches Targeting BCMA

In this expert-authored online activity gain case-based insights on incorporating new findings and novel agents targeting BCMA into the treatment paradigm for patients with multiple myeloma. Also featuring downloadable slides a Clinical Trial Spotlight resource and expert commentaries.

Share

Program Content

Activities

BCMA CAR T-Cell in MM
Targeting BCMA in Myeloma With CAR T-Cell Therapy
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: September 22, 2020

Expires: September 21, 2021

BCMA ADC/Bispecific Agents in MM
Targeting BCMA in Myeloma With Antibody–Drug Conjugates and Bispecific Agents
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 12, 2020

Expires: November 11, 2021

Activities

ExpressPoints: BCMA in Myeloma
Emerging Therapies and Novel Approaches Targeting BCMA in Myeloma
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 23, 2020

Expires: October 22, 2021

Targeting BCMA in Myeloma: Slides
Targeting BCMA in Myeloma: Downloadable Slides
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 26, 2020

Expires: October 25, 2021

Activities

BCMA: Myeloma Clinical Trials
Clinical Trial Resource Guide To Novel Myeloma Therapies Targeting BCMA
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: November 05, 2020

Expires: November 04, 2021

Faculty

cover img faculity

Natalie S. Callander, MD

Professor of Medicine
School of Medicine and Public Health
University of Wisconsin
Director, Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Celgene